BioPharma Dive June 7, 2023
Dive Brief:
- Bitterroot Bio emerged from stealth on Wednesday with $145 million in funding and plans to use a class of antibodies best known as potential cancer immunotherapies to treat heart disease.
- Backed by Arch Venture Partners, GV and a group of other well-known investors, the startup was spun out of the lab of Stanford University professor Irv Weissman, who is credited with discovering how tumors use the protein CD47 to evade the immune system. Weissman also co-founded Forty Seven, which Gilead acquired for about $5 billion in 2020, and another cancer biotech called Pheast Therapeutics.
- Bitterroot believes CD47 drugs have potential in reducing the risk of heart disease, too, and has raised its funding to test the theory....
Today's Sponsors
Today's Sponsor